CDT-WEST Center of Diagnostics and Therapy
| ドイツ | トルコ | オーストリア | |
| 骨髄移植術 | から $180,000 | から $36,000 | から $140,000 |
| 非血縁者間同種骨髄移植術 | から $160,000 | から $80,000 | から $180,000 |
| 自家骨髄移植術 | から $150,000 | から $31,500 | から $50,000 |
| 同種骨髄移植術 | から $150,000 | から $65,000 | から $150,000 |
| 乳癌化学療法 | から $4,500 | から $1,200 | から $15,000 |
Bookimedは急性リンパ性白血病治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。急性リンパ性白血病治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。急性リンパ性白血病治療の旅路でお一人になることはありません。
フォックス・ヴィオラ博士は、BKZゾーリンゲン血液腫瘍科・緩和医療科の主任医師です。同クリニックは、認定された集学的腫瘍センターです。フォックス博士は、ドイツおよびヨーロッパにおける腫瘍性疾患の薬物療法の第一人者であり、15年以上の臨床経験を有しています。
同博士は、ドイツ腫瘍学・血液腫瘍学会（GDHO）、ドイツ医師会、およびアメリカがん研究学会に所属しています。また、分子生物学の研究にも従事しており、その研究成果はがん治療および分子診断の発展に貢献しています。
主な専門領域は、化学療法、免疫療法、分子標的療法、および放射線療法です。フォックス博士は、革新的な治療法と患者への細やかな配慮で知られています。その取り組みにより、高い治癒率を達成し、同僚からの高い評価を得ています。
エルケ・イェーガー教授は、フォーカス誌の評価によるドイツトップクラスの腫瘍専門医であり、ノルドウェスト病院の腫瘍内科・血液内科を率いています。
Top certified hospitals for adult and pediatric Acute Lymphoblastic Leukemia (ALL) in Germany include Charité Berlin, Essen University Hospital, and University Hospital Heidelberg. These Comprehensive Cancer Centers (CCC) are jointly certified by the German Cancer Society and German Cancer Aid, ensuring high volume standards and access to European clinical trial protocols.
Bookimed Expert Insight: While many search for the highest medical reputation, patient volume is your strongest reliable quality signal. Essen University Hospital and Charité handle over 1.2 million combined patient visits annually. This massive volume means their specialists, like Dr. Bernd Hertenstein or Dr. Dietrich W. Beelen, manage rare ALL complications more frequently than regional centers. Choosing a university clinic ensures you stay within established protocols like GMALL or AIEOP-BFM without needing to transfer for specialized transplant care.
Patient Consensus: Patients note it is important to choose a facility where you can manage induction therapy through to transplant in one place. Families of children with ALL emphasize that sticking to strict clinical trial protocols is more valuable than luxury hospital amenities.
Standard ALL treatment in Germany follows a highly structured five-phase sequence. Protocols are risk-adapted based on the German Multicenter Study Group for Adult ALL (GMALL) or Berlin-Frankfurt-Münster (BFM) standards. These phases ensure complete remission while targeting residual cells to prevent recurrence.
Bookimed Expert Insight: While pediatric protocols are famous for success, Germany stands out for applying these rigorous standards to adults. High-volume centers like Essen University Hospital combine research with active clinical trials. This integration means patients often access emerging drugs before they reach general clinics worldwide.
Patient Consensus: Getting into remission after the induction phase is only the start. Patients note that later phases are critical for a cure and require careful infection prevention throughout the process.
ALL treatment in Germany delivers over 92% 5-year survival for children. German adults see a 46.4% 5-year survival rate according to registry data. Centralized trial networks and age-stratified protocols ensure standardized care. Specialized centers utilize advanced MRD tracking to guide therapy adjustments.
Bookimed Expert Insight: While overall adult survival sits near 46%, choosing a transplant-center university hospital is vital. Large institutions like Charité Berlin or Essen University Hospital handle massive patient volumes. Essen serves 370,000 patients annually and leads in transplant research. High-volume centers often provide better access to CAR NK cell therapy and clinical trials.
Patient Consensus: Patients note that achieving minimal residual disease negativity after induction is the most reassuring indicator. They emphasize that while cure rates are high for children, adult treatment requires intense monitoring and long-term maintenance.
Germany utilizes next-generation CAR T-cell therapy, bispecific T-cell engagers like Blinatumomab, and antibody-drug conjugates for relapsed ALL. Major university hospitals certified by the German Cancer Society provide these cellular immunotherapies and targeted tyrosine kinase inhibitors. These centers offer advanced pathways for patients who have exhausted traditional chemotherapy.
Bookimed Expert Insight: German university hospitals like Charite Berlin and Essen University Hospital manage massive volumes, serving over 370,000 to 800,000 patients yearly. This scale allows these centers to host the specialized infrastructure required for complex cell manufacturing. Patients should prioritize these high-volume university clinics because they often coordinate the GMALL trials. These trials provide access to inhibitors not yet available in smaller municipal hospitals.
Patient Consensus: Patients emphasize the need for molecular testing specifically for the Philadelphia chromosome to unlock targeted inhibitors. They note that while advanced therapies are effective, they often require longer hospital stays for intensive monitoring.
German medical care for acute lymphoblastic leukemia adheres to centralized, academic protocols overseen by national study groups. Facilities like Essen University Hospital integrate clinical research with patient treatment. Precise molecular auditing ensures high-precision monitoring of minimal residual disease throughout therapy.
Bookimed Expert Insight: High-volume university centers like Charité Berlin or Essen University Hospital offer a distinct advantage. These institutions serve over 370,000 patients annually and double as research hubs. Data suggests these centers provide more reliable anticipatory guidance for managing complex infection risks during induction phases.
Patient Consensus: Patients note that care follows extremely strict protocol schedules with little variation. They emphasize that any fever is treated as a severe medical emergency requiring immediate hospital presentation.